Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, including the assumption of debt. The acquisition will propel Sun Pharma into the top 25 largest pharmaceutical companies globally. The deal is expected to close by the end of 2025, subject to regulatory approvals and customary closing conditions. Sun Pharma, based in Mumbai, India, is one of the world's leading generic drugmakers. Organon, headquartered in Jersey City, New Jersey, is a global healthcare company focused on women's health. The acquisition will significantly expand Sun Pharma's portfolio in women's health and biosimilars, and provide access to Organon's established commercial infrastructure in key markets. Sun Pharma's Chairman, Dilip Shanghvi, stated that the acquisition aligns with the company's strategy to build a global specialty business. Organon's CEO, Kevin Ali, expressed confidence that the combined entity will better serve patients worldwide. The transaction is structured as a merger, with Organon shareholders receiving $31.00 per share in cash. Sun Pharma plans to finance the deal through a combination of existing cash reserves and debt financing. The acquisition is one of the largest in the Indian pharmaceutical industry's history.